Literature DB >> 1879438

The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells.

V R Sheridan1, L A Speicher, K D Tew.   

Abstract

The chemotherapeutic drug, estramustine, has been shown to cause the disassembly of microtubules via binding to microtubule-associated proteins. In this report, estramustine is shown to be a potent inhibitor of mitotic progression in the human prostatic carcinoma cell line, DU 145. Examination of individual living cells via video-enhanced differential interference contrast (DIC) optics shows that the drug delays the onset of anaphase, reduces anaphase spindle-pole elongation (anaphase B), and delays cytokinesis. In addition, immunofluorescent studies demonstrate that estramustine causes a rapid disorganization of the mitotic apparatus at significantly lower concentrations than those reported previously. Electron microscopic studies show that microtubule bundles are present in drug-treated mitotic cells in association with kinetochores and centrioles.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1879438

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  8 in total

1.  Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action.

Authors:  D Panda; H P Miller; K Islam; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

2.  Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study.

Authors:  D Yoshida; S Hoshino; T Shimura; H Takahashi; A Teramoto
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

Review 3.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

4.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.

Authors:  M A Jordan; R J Toso; D Thrower; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

5.  Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells.

Authors:  A T Bergenheim; M Hartman; J Bergh; P A Ridderheim; R Henriksson
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  The antineoplastic agent estramustine and the derivative estramustine-phosphate inhibit secretion of interleukin-3 in leukemic cells. Possible roles of MAPs.

Authors:  J Martínez; J F Santibáñez; C Vial; R B Maccioni
Journal:  Mol Cell Biochem       Date:  1992-11-18       Impact factor: 3.396

7.  Radiosensitizing effect of estramustine in malignant glioma in vitro and in vivo.

Authors:  A T Bergenheim; B Zackrisson; J Elfverson; G Roos; R Henriksson
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.

Authors:  L A Speicher; V R Sheridan; A K Godwin; K D Tew
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.